Abbvie Inc. Common Stock (ABBV) 53.27 $ABBV
1 Breakthrough, 3 Beneficiaries: AbbVie Inc., Bristol Myers Squibb Co., and Celgene Corporation
Keith Speights, The Motley Fool - Motley Fool - Wed May 21, 5:30PM CDT
A little good news can sometimes go a long way. On Monday, Bristol-Myers Squibb and AbbVie announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for multiple myeloma drug elotuzumab. This news bodes...
AbbVie's Humira Gets Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 3:30PM CDT
AbbVie Inc. (ABBV) announced that Humira has received orphan drug designation from the U.S. Food and Drug Administration.
The Bull Thesis for Pharmacyclics Into ASCO '14
at The Street - Wed May 21, 7:00AM CDT
If we get complete response rates from Imbruvica-Arzerra similar to what's being reported for Abbvie's ABT-199, that would be positive for Pharmacyclics
AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis
PR Newswire - Tue May 20, 2:49PM CDT
AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical program is in Phase III development. HUMIRA is not currently approved to treat any form of uveitis.
FDA Designation for Bristol-Myers/AbbVie Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 20, 10:40AM CDT
Bristol-Myers (BMY) and AbbVie (ABBV) announced that the FDA has granted breakthrough therapy designation to elotuzumab.
Global B-Cell Chronic Lymphocytic Leukemia Therapeutics Pipeline Review H1 2014 - 13 Companies & 23 Drug Profiles
M2 - Tue May 20, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sztpvs/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Involved in Therapeutics Development - Biogen Idec Inc. - rEVO Biologics - Nippon Shinyaku Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Immunomedics, Inc. - MABLife S.A.S - SBI Biotech Co., Ltd. - Neopharm Ltd. - Advancell - Vivia Biotech, S.L. - AbbVie Inc. - BioNovion B.V. - TheraMAB LLC. Drug Profiles - acadesine - bafetinib - rituximab - Allogeneic CD19CAR-TCM cells - FBTA-05 - CD19.CAR-CD28Z T Cells - CD19 Specific T Cell - GNKG-168 - ilorasertib - ONO-4059 - Allogeneic Cell Therapy Tumor-Derived Lymphocytes - Gene Modified T Cells for Leukemia - TG-20 - MAT-304 - Vivia-009 - Monoclonal Antibody Targeting APRIL - alemtuzumab biosimilar - GNKS-356 - TAB-08 - Central Memory T Cell Therapy For Cancer - 202-b - Xanthone Derivatives For Cancer - alemtuzumab biosimilar For more information visit http://www.researchandmarkets.com/research/sz...ll_chronic
Global Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Pipeline Review 2014 - 15 Companies & 18 Drug Profiles
M2 - Tue May 20, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7s7x97/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Novartis AG - Astex Pharmaceuticals, Inc. - Celgene Corporation - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - SBI Biotech Co., Ltd. - AbbVie Inc. - SpectraMab GmbH Drug Profiles - ibrutinib - duvelisib - venetoclax - venetoclax rituximab - AT-7519 - MOR-208 - MEDI-551 - CTL-019 - afuresertib - PRT-2070 - Gene Modified T Cells for Leukemia - TH-302 - GNKG-168 - CC-292 - BMS-986016 - AZD-6738 - venetoclax obinutuzumab - Triplebody 19x16x19 For more information visit http://www.researchandmarkets.com/research/7s7x97/refractory
Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell
Morning Analysis on Active Equities -- Research on AbbVie, Johnson Controls, DISH, and CEMEX
PR Newswire - Tue May 20, 7:50AM CDT
The markets on Monday, May 19, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,511.86, up 0.12% and the NASDAQ Composite closed at 4,125.82, up 0.86%. The S&P 500 edged 0.38% higher, to finish the day at 1,885.08. The gains were broad based as seven out of ten sectors ended the session in positive. During the session gains in the Financials, Information Technology and Health Care sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Utilities and Telecommunication Services sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include AbbVie Inc. (NYSE: ABBV), Johnson Controls Inc. (NYSE: JCI), DISH Network Corporation (NASDAQ: DISH) and CEMEX S.A.B. de C.V. (NYSE: CX). Free technical research on ABBV, JCI, DISH and CX can be downloaded upon signing up at:
AbbVie to Present at 2014 UBS Global Healthcare Conference
PR Newswire - Tue May 20, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the 2014 UBS Global Healthcare Conference on Wednesday, May 21, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 9:30 a.m. Central time.
Bristol-Myers Squibb and AbbVie announces receipt of US FDA breakthrough therapy designation for Elotuzumab
M2 - Tue May 20, 5:17AM CDT
Global biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV), a research-based biopharmaceutical company, on Monday announced the grant by the US Food and Drug Administration (FDA) of Breakthrough Therapy Designation for elotuzumab, an investigational humanized monoclonal antibody, for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.
Abbott to Buy CFR Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 11:00AM CDT
In a move to broaden its presence in the Latin American market, Abbott Labs (ABT) announced that it has entered into a definitive agreement to acquire CFR Pharmaceuticals.
FDA to give blood cancer drug faster review
By The Associated Press - AP - Mon May 19, 8:58AM CDT
A potential blood cancer treatment from drugmakers AbbVie and Bristol-Myers Squibb has been named a "breakthrough therapy" by the Food and Drug Administration, a designation designed to speed up the drug's testing and approval process.
Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma
Business Wire - Mon May 19, 7:01AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies. The designation is based on findings from a randomized Phase 2, open-label study that evaluated two dose levels of elotuzumab in combination with lenalidomide and low-dose dexamethasone in previously-treated patients, including the 10 mg/kg dose that is being studied in Phase 3 trials. Data from the Phase 2 trial were most recently presented at the 18th Annual Congress of the European Hematology Association (EHA) in 2013 (click here to view press release).
Abbott Labs Buying Latin American Drug Giant CFR
at Investor's Business Daily - Fri May 16, 10:58AM CDT
Medical-products giant Abbott Laboratories (ABT) agreed on Friday to buy Chilean drugmaker CFR Pharmaceuticals for $2.9 billion. Abbott stock dipped a fraction in heavy trading on the stock market today. The deal, which also involves Abbott's...
AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement
PR Newswire - Thu May 15, 11:00AM CDT
AbbVie (NYSE: ABBV) has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino's track record of innovation within the biotech industry aligns with AbbVie's vision as a new biopharmaceutical leader with a rapidly emerging pipeline.
Marketing Authorization Applications, Clinical Trial Results, Awards & Recognitions, and Resources Expansions - Analyst Notes on AbbVie, Medtronic, Abbott, Zimmer and Arena
PR Newswire - Thu May 15, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc (NYSE: ABBV), Medtronic, Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Zimmer Holdings, Inc. (NYSE: ZMH) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2471-100free.
ASCO '14 Preview: Blood Cancer Data from Pharmacyclics, Gilead, Abbvie
at The Street - Wed May 14, 4:00PM CDT
All three companies will be presented updates results on drugs used to treat chronic lymphocytic leukemia.
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.
Critical Alerts For PepsiCo, Salesforce.com, Fortinet, Total SA, and AbbVie Released By InvestorsObserver
PR Newswire - Tue May 13, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PEP, CRM, FTNT, TOT, and ABBV.
1 Breakthrough, 3 Beneficiaries: AbbVie Inc., Bristol Myers Squibb Co., and Celgene Corporation
Keith Speights, The Motley Fool - Motley Fool - Wed May 21, 5:30PM CDT
A little good news can sometimes go a long way. On Monday, Bristol-Myers Squibb and AbbVie announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for multiple myeloma drug elotuzumab. This news bodes...
AbbVie's Humira Gets Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 3:30PM CDT
AbbVie Inc. (ABBV) announced that Humira has received orphan drug designation from the U.S. Food and Drug Administration.
The Bull Thesis for Pharmacyclics Into ASCO '14
at The Street - Wed May 21, 7:00AM CDT
If we get complete response rates from Imbruvica-Arzerra similar to what's being reported for Abbvie's ABT-199, that would be positive for Pharmacyclics
AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis
PR Newswire - Tue May 20, 2:49PM CDT
AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical program is in Phase III development. HUMIRA is not currently approved to treat any form of uveitis.
FDA Designation for Bristol-Myers/AbbVie Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 20, 10:40AM CDT
Bristol-Myers (BMY) and AbbVie (ABBV) announced that the FDA has granted breakthrough therapy designation to elotuzumab.
Global B-Cell Chronic Lymphocytic Leukemia Therapeutics Pipeline Review H1 2014 - 13 Companies & 23 Drug Profiles
M2 - Tue May 20, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sztpvs/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Involved in Therapeutics Development - Biogen Idec Inc. - rEVO Biologics - Nippon Shinyaku Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Immunomedics, Inc. - MABLife S.A.S - SBI Biotech Co., Ltd. - Neopharm Ltd. - Advancell - Vivia Biotech, S.L. - AbbVie Inc. - BioNovion B.V. - TheraMAB LLC. Drug Profiles - acadesine - bafetinib - rituximab - Allogeneic CD19CAR-TCM cells - FBTA-05 - CD19.CAR-CD28Z T Cells - CD19 Specific T Cell - GNKG-168 - ilorasertib - ONO-4059 - Allogeneic Cell Therapy Tumor-Derived Lymphocytes - Gene Modified T Cells for Leukemia - TG-20 - MAT-304 - Vivia-009 - Monoclonal Antibody Targeting APRIL - alemtuzumab biosimilar - GNKS-356 - TAB-08 - Central Memory T Cell Therapy For Cancer - 202-b - Xanthone Derivatives For Cancer - alemtuzumab biosimilar For more information visit http://www.researchandmarkets.com/research/sz...ll_chronic
Global Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Pipeline Review 2014 - 15 Companies & 18 Drug Profiles
M2 - Tue May 20, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7s7x97/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Novartis AG - Astex Pharmaceuticals, Inc. - Celgene Corporation - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - SBI Biotech Co., Ltd. - AbbVie Inc. - SpectraMab GmbH Drug Profiles - ibrutinib - duvelisib - venetoclax - venetoclax rituximab - AT-7519 - MOR-208 - MEDI-551 - CTL-019 - afuresertib - PRT-2070 - Gene Modified T Cells for Leukemia - TH-302 - GNKG-168 - CC-292 - BMS-986016 - AZD-6738 - venetoclax obinutuzumab - Triplebody 19x16x19 For more information visit http://www.researchandmarkets.com/research/7s7x97/refractory
Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell
Morning Analysis on Active Equities -- Research on AbbVie, Johnson Controls, DISH, and CEMEX
PR Newswire - Tue May 20, 7:50AM CDT
The markets on Monday, May 19, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,511.86, up 0.12% and the NASDAQ Composite closed at 4,125.82, up 0.86%. The S&P 500 edged 0.38% higher, to finish the day at 1,885.08. The gains were broad based as seven out of ten sectors ended the session in positive. During the session gains in the Financials, Information Technology and Health Care sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Utilities and Telecommunication Services sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include AbbVie Inc. (NYSE: ABBV), Johnson Controls Inc. (NYSE: JCI), DISH Network Corporation (NASDAQ: DISH) and CEMEX S.A.B. de C.V. (NYSE: CX). Free technical research on ABBV, JCI, DISH and CX can be downloaded upon signing up at:
AbbVie to Present at 2014 UBS Global Healthcare Conference
PR Newswire - Tue May 20, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the 2014 UBS Global Healthcare Conference on Wednesday, May 21, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 9:30 a.m. Central time.
Bristol-Myers Squibb and AbbVie announces receipt of US FDA breakthrough therapy designation for Elotuzumab
M2 - Tue May 20, 5:17AM CDT
Global biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV), a research-based biopharmaceutical company, on Monday announced the grant by the US Food and Drug Administration (FDA) of Breakthrough Therapy Designation for elotuzumab, an investigational humanized monoclonal antibody, for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.
Abbott to Buy CFR Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 11:00AM CDT
In a move to broaden its presence in the Latin American market, Abbott Labs (ABT) announced that it has entered into a definitive agreement to acquire CFR Pharmaceuticals.
FDA to give blood cancer drug faster review
By The Associated Press - AP - Mon May 19, 8:58AM CDT
A potential blood cancer treatment from drugmakers AbbVie and Bristol-Myers Squibb has been named a "breakthrough therapy" by the Food and Drug Administration, a designation designed to speed up the drug's testing and approval process.
Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma
Business Wire - Mon May 19, 7:01AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies. The designation is based on findings from a randomized Phase 2, open-label study that evaluated two dose levels of elotuzumab in combination with lenalidomide and low-dose dexamethasone in previously-treated patients, including the 10 mg/kg dose that is being studied in Phase 3 trials. Data from the Phase 2 trial were most recently presented at the 18th Annual Congress of the European Hematology Association (EHA) in 2013 (click here to view press release).
Abbott Labs Buying Latin American Drug Giant CFR
at Investor's Business Daily - Fri May 16, 10:58AM CDT
Medical-products giant Abbott Laboratories (ABT) agreed on Friday to buy Chilean drugmaker CFR Pharmaceuticals for $2.9 billion. Abbott stock dipped a fraction in heavy trading on the stock market today. The deal, which also involves Abbott's...
AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement
PR Newswire - Thu May 15, 11:00AM CDT
AbbVie (NYSE: ABBV) has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino's track record of innovation within the biotech industry aligns with AbbVie's vision as a new biopharmaceutical leader with a rapidly emerging pipeline.
Marketing Authorization Applications, Clinical Trial Results, Awards & Recognitions, and Resources Expansions - Analyst Notes on AbbVie, Medtronic, Abbott, Zimmer and Arena
PR Newswire - Thu May 15, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc (NYSE: ABBV), Medtronic, Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Zimmer Holdings, Inc. (NYSE: ZMH) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2471-100free.
ASCO '14 Preview: Blood Cancer Data from Pharmacyclics, Gilead, Abbvie
at The Street - Wed May 14, 4:00PM CDT
All three companies will be presented updates results on drugs used to treat chronic lymphocytic leukemia.
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.
Critical Alerts For PepsiCo, Salesforce.com, Fortinet, Total SA, and AbbVie Released By InvestorsObserver
PR Newswire - Tue May 13, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PEP, CRM, FTNT, TOT, and ABBV.
